Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.58 EUR | +1.30% | -0.84% | +14.10% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 32 and 27.65 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.10% | 51.28B | - | ||
+8.55% | 219B | B | ||
+8.14% | 185B | B- | ||
+14.75% | 135B | B- | ||
+27.70% | 107B | A- | ||
+4.88% | 51.01B | B+ | ||
+3.73% | 41.85B | A | ||
+6.62% | 37.02B | - | ||
+24.89% | 31.27B | B+ | ||
+17.61% | 23.66B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- EWL Stock
- Ratings Edwards Lifesciences Corporation